Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(1.35) by 87.41 percent. This is a 95.53 percent increase over losses of $(3.80) per share from the same period last year.
Related Posts
Truist Securities Maintains Buy on O’Reilly Automotive, Lowers Price Target to $770
Truist Securities analyst Scot Ciccarelli maintains O'Reilly Automotive (NASDAQ:ORLY) with a Buy and lowers the price target from $788 to $770.
Rising Wait Times And Higher Pricing For Uber? It Is Because Mobility Demand Has Hit Peak Levels, Analyst Says
Needham analyst Bernie McTernan reiterated a Buy on Uber Technologies, Inc (NYSE:UBER) with a $52 price target. In his 14th Mobility Tracker, wait…
How To Attend Goldman Sachs Gr Q1 2023 Earnings Conference Call
Goldman Sachs Gr (NYSE:GS) will host a conference call at 09:30 AM ET on April 18, 2023, to…